Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corona RemediesBOM:544644 +0.73%18 Pretax Margin % is 19.02% as of Jun. 2026, which is 30% above its 10-year median of 14.58. GuruFocus rates BOM:544644 with a GF Score™ of 18/100. The stock has 4 warning signs investors should review. Among 960 Drug Manufacturers companies, Corona Remedies ranks better than 75.52% on this metric.
The historical rank and industry rank for Corona Remedies's Pretax Margin % or its related term are showing as below:
BOM:544644'
s Pretax Margin % Range Over the Past 10 Years
Min: 11.69 Med: 14.58 Max: 17.15
Current: 17.02
BOM:544644's Pretax Margin % is ranked better than 75.52% of 960
companies
in the Drug Manufacturers industry
Industry Median: 7.045
vs BOM:544644: 17.02
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Corona Remedies Pretax Margin % Related Terms
Corona Remedies Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Corona Remedies's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544644 vs LLY, JNJ, ABBV: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, Corona Remedies's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corona Remedies Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Corona Remedies's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Corona Remedies's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corona Remedies (BOM:544644) has a Pretax Margin % of 19.02% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Corona Remedies and its competitors. This is 30% above median its historical median of 14.58. Over the past decade, Corona Remedies' Pretax Margin % has ranged from 11.69 to 17.15. According to the industry distribution chart, Corona Remedies ranks #235 out of 960 companies in the Drug Manufacturers industry, placing it in the top 24.5%.
Is Corona Remedies' Pretax Margin % too high?
Corona Remedies' current Pretax Margin % of 19.02% is 30% above median its 10-year median of 14.58. Over the past 10 years, this metric has ranged from a low of 11.69 to a high of 17.15. The Drug Manufacturers industry median Pretax Margin % is 7.05. Corona Remedies' value of 19.02% is 170% above this industry median. Based on the distribution chart, Corona Remedies ranks #235 out of 960 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' Pretax Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Corona Remedies ranks #235 out of 960 companies for Pretax Margin %. This places Corona Remedies in the top 25% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.05. Corona Remedies' value of 19.02% is 170% above this benchmark. Historically, Corona Remedies' own Pretax Margin % has ranged from 11.69 to 17.15 over the past decade. While the company's 10-year median is 14.58 vs. the industry median of 7.05, Corona Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.05, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corona Remedies's current Pretax Margin % of 19.02% is 170% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Corona Remedies and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corona Remedies's current Pretax Margin % is 19.02%, which is 30% above median its own 10-year median of 14.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (BOM:544644) has a current Pretax Margin % of 19.02%. The current Pretax Margin % is 19.02%, which is 30% above median its 10-year median of 14.58 and 170% above the Drug Manufacturers industry median of 7.05. Corona Remedies' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Corona Remedies (BOM:544644), the current Pretax Margin % is 19.02% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score
Get the complete analysis for BOM:544644
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544644 has been successfully added to your 
